Should I buy or sell Genfit stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genfit in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GNFT shares. View GNFT analyst ratings or view top-rated stocks .

What is Genfit's stock price target for 2024?

2 brokers have issued 1 year target prices for Genfit's stock. Their GNFT share price targets range from $4.00 to $11.00. On average, they predict the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 135.8% from the stock's current price. View analysts price targets for GNFT or view top-rated stocks among Wall Street analysts .

How have GNFT shares performed in 2023?

Genfit's stock was trading at $4.3890 at the beginning of 2023. Since then, GNFT stock has decreased by 27.5% and is now trading at $3.18. View the best growth stocks for 2023 here .

What is Jean-François Mouney's approval rating as Genfit's CEO?

3 employees have rated Genfit Chief Executive Officer Jean-François Mouney on Glassdoor.com . Jean-François Mouney has an approval rating of 29% among the company's employees. This puts Jean-François Mouney in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Genfit own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genfit investors own include Intercept Pharmaceuticals (ICPT) , InterDigital (IDCC) , STAG Industrial (STAG) , Gilead Sciences (GILD) , Occidental Petroleum (OXY) , Vaxart (VXRT) , Exxon Mobil (XOM) , Zynerba Pharmaceuticals (ZYNE) , Aimmune Therapeutics (AIMT) and Amarin (AMRN) .

(GNFT) raised $132 million in an IPO on Wednesday, March 27th 2019. The company issued 5,000,000 shares at $26.33 per share. SVB Leerink and Barclays acted as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.

Who are Genfit's major shareholders?

Genfit's stock is owned by a number of institutional and retail investors. Top institutional shareholders include O Shaughnessy Asset Management LLC (0.03%).

How do I buy shares of Genfit?

Shares of GNFT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Genfit Stock Price, News & Analysis (NASDAQ:GNFT)

$3.18

-0.08 (-2.45%)

(As of 12/4/2023 ET)

Compare

Today's Range: $3.18
▼
$3.19
50-Day Range: $2.97
▼
$3.40
52-Week Range: $2.89
▼
$4.75

Volume: 37,487 shs
Average Volume: 39,008 shs
Market Capitalization: $158.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.50

Genfit MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 135.8% Upside
$7.50 Price Target
Short Interest: Bearish
0.22% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.23) to $0.50 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.72 out of 5 stars

Medical Sector

705th out of 952 stocks

Biological Products, Except Diagnostic Industry

115th out of 155 stocks

3.5

Analyst's Opinion

Consensus Rating
Genfit has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.50, Genfit has a forecasted upside of 135.8% from its current price of $3.18.
Amount of Analyst Coverage
Genfit has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
0.22% of the float of Genfit has been sold short.
Short Interest Ratio / Days to Cover
Genfit has a short interest ratio ("days to cover") of 4.7.
Change versus previous month
Short interest in Genfit has recently increased by 0.57%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Genfit does not currently pay a dividend.
Dividend Growth
Genfit does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GNFT.

N/A

News and Social Media Coverage

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Genfit insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.20% of the stock of Genfit is held by insiders.
Percentage Held by Institutions
Only 8.82% of the stock of Genfit is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Genfit are expected to grow in the coming year, from ($0.23) to $0.50 per share.
Price to Book Value per Share Ratio
Genfit has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Genfit Stock (NASDAQ:GNFT)

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

GNFT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GNFT Stock News Headlines

November 17, 2023 | benzinga.com

GENFIT Highlights ACLF Development Strategy at "ACLF Day" during AASLD The Liver Meeting® 2023

November 9, 2023 | finance.yahoo.com

GENFIT Reports Third Quarter 2023 Financial Information

December 5, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 9, 2023 | msn.com

Oil Stocks Buoy European Equities Traded in the US as American Depositary Receipts Thursday

November 7, 2023 | msn.com

Oil Stocks Burden European Equities Traded in the US as American Depositary Receipts Tuesday

September 26, 2023 | finance.yahoo.com

GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology

September 26, 2023 | finance.yahoo.com

GENFIT S.A. Unsponsored ADR (GNFT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

September 22, 2023 | finanznachrichten.de

GENFIT S.A.: GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update

December 5, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

September 20, 2023 | finance.yahoo.com

GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update

September 15, 2023 | fool.com

Genfit (NASDAQ: GNFT)

August 16, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Higher Wednesday

August 14, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Start Week on Down Note

June 30, 2023 | msn.com

Genfit’s Liver Disease Candidate Delivers Promising Phase 3 Results

June 16, 2023 | markets.businessinsider.com

Kepler Capital Keeps Their Buy Rating on Genfit (GNFTF)

June 8, 2023 | msn.com

PORTZAMPARC BNP PARIBAS Maintains Genfit (EPA:GNFT) Buy Recommendation

June 7, 2023 | finance.yahoo.com

GENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023

June 1, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Genfit SA (GNFT)

May 31, 2023 | finance.yahoo.com

Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF)

May 31, 2023 | finance.yahoo.com

GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset

May 23, 2023 | finance.yahoo.com

GENFIT Announces Publication of the Development and Validation of NIS2+™ in the Journal of Hepatology

April 19, 2023 | finance.yahoo.com

GENFIT Annual Combined General Meeting of May 24, 2023 — Availability of Preparatory Documents

January 5, 2023 | finance.yahoo.com

GENFIT to Participate in Upcoming Investor Conferences

October 10, 2022 | benzinga.com

12 Health Care Stocks Moving In Monday's Pre-Market Session - Acer Therapeutics (NASDAQ:ACER), Avadel Pha - Benzinga

October 7, 2022 | marketscreener.com

GENFIT : Pipeline Day - Corporate Presentation - October 2022 - Marketscreener.com

September 30, 2022 | globenewswire.com

GENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of Versantis - GlobeNewswire

September 28, 2022 | globenewswire.com

GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update - GlobeNewswire

See More Headlines

Receive GNFT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 12/05/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GNFT
CUSIP: N/A
CIK: 1757064
Web: www.genfit.com
Phone: (332) 016-4000
Fax: N/A
Employees: 154
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.50
High Stock Price Target: $11.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +135.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.91
Current Ratio: 2.95
Quick Ratio: 2.95

Sales & Book Value

Annual Sales: $28 million
Price / Sales: 5.66
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.00 per share
Price / Book: 1.59

Miscellaneous

Outstanding Shares: 49,830,000
Free Float: 47,742,000
Market Cap: $158.46 million
Optionable: Not Optionable
Beta: 1.08

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Jean-Francois Mouney (Age 68)
Co-Founder & Chairman of the Board
Comp: $401.85k
Mr. M. Pascal Prigent (Age 55)
Chief Executive Officer
Comp: $609.01k
Prof. Bart Staels (Age 60)
Co-Founder & Chairman of the Scientific Advisory Board
Mr. Thomas Baetz (Age 49)
Chief Financial Officer
Mr. Pascal Caisey (Age 55)
Chief Operating Officer
Dr. Meriam Kabbaj Ph.D. (Age 49)
Chief Technology Officer
Dr. Dean W. Hum Ph.D. (Age 61)
Chief Scientific Officer
Comp: $774.94k
Mr. Jean-Christophe Marcoux (Age 45)
Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG
Mr. Laurent Lannoo (Age 53)
Corporate Secretary & Director of Legal Affairs
Ms. Stefanie Magner J.D. (Age 42)
Chief Compliance Officer & Executive VP of International Legal Affairs

Key Competitors

View All Competitors

Institutional Ownership

O Shaughnessy Asset Management LLC
Sold 18,822 shares on 11/14/2023
Ownership: 0.027%

View All Institutional Transactions

GNFT Stock Analysis - Frequently Asked Questions

Should I buy or sell Genfit stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genfit in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GNFT shares.
View GNFT analyst ratings or view top-rated stocks.
What is Genfit's stock price target for 2024?: 2 brokers have issued 1 year target prices for Genfit's stock. Their GNFT share price targets range from $4.00 to $11.00. On average, they predict the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 135.8% from the stock's current price.
View analysts price targets for GNFT or view top-rated stocks among Wall Street analysts.
How have GNFT shares performed in 2023?: Genfit's stock was trading at $4.3890 at the beginning of 2023. Since then, GNFT stock has decreased by 27.5% and is now trading at $3.18.
View the best growth stocks for 2023 here.
What is Jean-François Mouney's approval rating as Genfit's CEO?: 3 employees have rated Genfit Chief Executive Officer Jean-François Mouney on Glassdoor.com. Jean-François Mouney has an approval rating of 29% among the company's employees. This puts Jean-François Mouney in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Genfit own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Genfit investors own include Intercept Pharmaceuticals (ICPT), InterDigital (IDCC), STAG Industrial (STAG), Gilead Sciences (GILD), Occidental Petroleum (OXY), Vaxart (VXRT), Exxon Mobil (XOM), Zynerba Pharmaceuticals (ZYNE), Aimmune Therapeutics (AIMT) and Amarin (AMRN).
When did Genfit IPO?: (GNFT) raised $132 million in an IPO on Wednesday, March 27th 2019. The company issued 5,000,000 shares at $26.33 per share. SVB Leerink and Barclays acted as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.
Who are Genfit's major shareholders?: Genfit's stock is owned by a number of institutional and retail investors. Top institutional shareholders include O Shaughnessy Asset Management LLC (0.03%).
How do I buy shares of Genfit?: Shares of GNFT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GNFT) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial